Medical Management and Strategies to Prevent Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus

References

• . Centers for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services. Centers for Disease Control and Prevention, 2011
   Google Scholar
• . Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–2581
   PubMed Web of Science ®Google Scholar
• . Peele PB, Lave JR, Songer TJ. Diabetes in employer-sponsored health insurance. Diabetes Care. 2002;25(11):1964–1968
   PubMedGoogle Scholar
• . Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with or without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234
   PubMed Web of Science ®Google Scholar
• . Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy: part 2. Circulation. 2003;108(13):1655–1661
   PubMed Web of Science ®Google Scholar
• . Young LH, Wackers FJ, Chyun DA, ; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: arandomized controlled trial. JAMA. 2009;301(15):1547–1555
   PubMed Web of Science ®Google Scholar
• . Bastien A. The ACCORD trial: a multidisciplinary approach to control cardiovascular risk in type 2 diabetes mellitus. Pract Diabetol. 2004;23:6–11
   Google Scholar
• . Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393
   PubMed Web of Science ®Google Scholar
• . Braunwald E. Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337(19):1360–1369
   PubMed Web of Science ®Google Scholar
• . Sheikh—Ali M, Chehade JM, Mooradian AD. The antioxidant paradox in diabetes mellitus. Am J Ther. 2011;18(3):266–278
   PubMedGoogle Scholar
• . Cipollone F, Iezzi A, Fazia M, . The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003;108(9):1070–1077
   PubMedGoogle Scholar
• . Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26(7):2181–2188
   PubMed Web of Science ®Google Scholar
• . Varo N, Vicent D, Libby P, . Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation. 2003;107(21):2664–2669
   PubMed Web of Science ®Google Scholar
• . Colwell JA. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs. 2004;4(2):87–106
   PubMedGoogle Scholar
• . Sobel BE, Woodcock—Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation. 1998;97(22):2213–2221
   PubMedGoogle Scholar
• . Pandolfi A, Cetrullo D, Polishuck R, . Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol. 2001;21(8):1378–1382
   PubMed Web of Science ®Google Scholar
• . Juhan—Vague I, Roui C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients—relationship with plasma insulin. Thromb Haemost. 1989;61(3):370–373
   PubMedGoogle Scholar
• . Moreno PR, Murcia AM, Palacios IF, . Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102(18):2180–2184
   PubMed Web of Science ®Google Scholar
• . Marfella R, D'Amico M, Esposito K, . The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes. 2006;55(3):622–632
   PubMed Web of Science ®Google Scholar
• . Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553–1579
   PubMed Web of Science ®Google Scholar
• . Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ; American Diabetes Association. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007;30(10):2729–2736
   PubMedGoogle Scholar
• . Sorajja P, Chareonthaitawee P, Rajagopalan N, . Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation. 2005;112( 9 suppl):I311–I316
   Google Scholar
• . Faglia E, Manuela M, Antonella Q, . Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J. 2005;149(2):e1–e6
   PubMedGoogle Scholar
• . Bansal S, Wackers FJ, Inzucchi SE, ; DIAD Study Investigators. Five-year outcomes in high-risk participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study: a post hoc analysis. Diabetes Care. 2011;34(1):204–209
   PubMedGoogle Scholar
• . Wackers FJ, Chyun DA, Young LH, ; Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care. 2007;30(11):2892–2898
   PubMedGoogle Scholar
• . Fraker TD Jr, Fihn SD, Gibbons RJ, ; 2002 Chronic Stable Angina Writing Committee; American College of Cardiology; American Heart Association; et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50(23):2264–2274
   PubMed Web of Science ®Google Scholar
• . Frye RL, August P, Brooks MM, ; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–2515
   PubMed Web of Science ®Google Scholar
• . Chaitman BR, Hardison RM, Adler D, ; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009;120(25):2529–2540
   PubMedGoogle Scholar
• . Boden WE, O'Rourke RA, Teo KK, ; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–1516
   PubMed Web of Science ®Google Scholar
• . BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49(15):1600–1606
   PubMed Web of Science ®Google Scholar
• . Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96(6):1761–1769
   PubMed Web of Science ®Google Scholar
• . Kapur A, Hall RJ, Malik IS, . Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55(5):432–440
   PubMed Web of Science ®Google Scholar
• . Kapur A, Malik IS, Bagger JP, . The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J. 2005;149:13–19
   PubMed Web of Science ®Google Scholar
• . Farkouh ME, Dangas G, Leon MB, . Design of the Future Revascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J. 2008;155(2):215–223
   PubMed Web of Science ®Google Scholar
• . Buse JB, Ginsberg HN, Bakris GL, ; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114–126
   PubMed Web of Science ®Google Scholar
• . Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med. 2000;132(8):605–611
   PubMed Web of Science ®Google Scholar
• . Hu FB, Stampfer MJ, Solomon C, . Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med. 2001;134(2):96–105
   PubMed Web of Science ®Google Scholar
• . Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation. 2003;107(19):2435–2439
   PubMed Web of Science ®Google Scholar
• . US Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans, 2008. http://www.health.gov/paguidelines/guidelines/default.aspx. Accessed June 10, 2012
   Google Scholar
• . Sigal RJ, Kenny GP, Wasserman DH, Castaneda—Sceppa C, White RD. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29(6):1433–1438
   PubMed Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR, ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572
   PubMed Web of Science ®Google Scholar
• . Sacks FM, Svetkey LP, Vollmer WM, ; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3–10
   PubMed Web of Science ®Google Scholar
• . Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
   PubMed Web of Science ®Google Scholar
• . Greenland P, Alpert JS, Beller GA, . 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computer Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2010;56(25):e50–e103
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35( suppl 1):S11–S63
   PubMed Web of Science ®Google Scholar
• . Ranney L, Melvin C, Lux L, . Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145(11):845–856
   PubMed Web of Science ®Google Scholar
• . Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338(8):520–531
   PubMedGoogle Scholar
• . Bakris GL, Fonseca V, Katholy RE, ; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes and hypertension: a randomized control trial. JAMA. 2004;292(18):2227–2236
   PubMed Web of Science ®Google Scholar
• . Kopecky SL. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol. 2006;98(8):1115–1119
   PubMedGoogle Scholar
• . Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers. J Clin Hypertens (Greenwich). 2011;13(1):52–59
   PubMed Web of Science ®Google Scholar
• . Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med. 1982;307(26):1618–1627
   PubMedGoogle Scholar
• . Nesto RW, Zarich S. Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition. Circulation. 1998;97(1):12–15
   PubMed Web of Science ®Google Scholar
• . Gustafsson I, Torp—Pedersen C, Køber L, Gustafsson F, Hildebrandt P; TRACE Study Group. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol. 1999;34(1):83–89
   PubMedGoogle Scholar
• . Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation. 1997;96(12):4239–4245
   PubMed Web of Science ®Google Scholar
• . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253–259
   PubMed Web of Science ®Google Scholar
• . Lindholm LH, Ibsen H, Dahlof B, ; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004–1010
   PubMed Web of Science ®Google Scholar
• . Werner C, Baumhakel M, Teo KK, . RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97(7):418–431
   PubMedGoogle Scholar
• . Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Teo KK, Pogue J, ; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . Shmieder RE, Mann JF, Schumacher H, ; ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol. 2011;22(7):1353–1364
   PubMedGoogle Scholar
• . Tekturna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012
   Google Scholar
• . Parving HH, Brenner BM, McMurray JJ, . Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24(5):1663–1671
   PubMed Web of Science ®Google Scholar
• . Novartis. Novartis announces termination of ALTITUDE study with Rasilez®/Tekturna® in high-risk patients with diabetes and renal impairment [mediarelease], http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml. Released December 20, 2011. Accessed June 20, 2012
   Google Scholar
• . Smith SC Jr, Benjamin EJ, Bonow RO, ; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–2473
   PubMed Web of Science ®Google Scholar
• . Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med. 1989;321(3):129–135
   PubMed Web of Science ®Google Scholar
• . Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology. 1991;98( 5 suppl):757–765
   PubMedGoogle Scholar
• . Hansson L, Zanchetti A, Carruthers SG, ; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351(9118):1755–1762
   PubMed Web of Science ®Google Scholar
• . Krein SL, Vijan S, Pogach LM, Hogan MM, Kerr EA. Aspirin use and counseling about aspirin among patients with diabetes. Diabetes Care. 2002;25(6):965–970
   PubMedGoogle Scholar
• . Berent R, Sinzinger H. “Aspirin—resistance”? A few critical considerations on definition, terminology, diagnosis, clinical value, natural course of atherosclerotic disease, and therapeutic consequences. Vasa. 2011;40(6):429–438
   PubMedGoogle Scholar
• . Yusuf S, Zhao F, Mehta SR, ; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502
   PubMed Web of Science ®Google Scholar
• . Steinhubl SR, Berger PB, Mann JT 3rd, ; CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–2420
   PubMed Web of Science ®Google Scholar
• . Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of Clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90(6):625–628
   PubMed Web of Science ®Google Scholar
• . Angiolillo DJ, Shoemaker SB, Desai B, . Randomized comparison of a high Clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007;115(6):708–716
   PubMed Web of Science ®Google Scholar
• . Bennett CL, Weinberg PD, Rozenberg—Ben—Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. Areview of 60 cases. Ann Intern Med. 1998;128(7):541–544
   PubMed Web of Science ®Google Scholar
• . Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care. 1990;13(2):153–169
   PubMed Web of Science ®Google Scholar
• . Baigent C, Blackwell L, Emberson J, ; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681
   PubMed Web of Science ®Google Scholar
• . Colhoun HM, Betteridge DJ, Durrington PN, ; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet. 2004;364(9435):685–696
   PubMed Web of Science ®Google Scholar
• . Tonkin A, Hunt D, Voysey M, ; FIELD Study Investigators. Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Am Heart J. 2012;163(3):508–514
   PubMedGoogle Scholar
• . Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study—4S. Lancet. 1994;344(8934):1383–1389
   PubMed Web of Science ®Google Scholar
• . Sever PS, Poulter NR, Dahlöf B, . Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo Scandinavian Cardiac Outcome Trial-Lipid-Lowering Arm. Diabetes Care. 2005;28(5):1151–1157
   PubMed Web of Science ®Google Scholar
• . Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: arandomized placebo-controlled trial. Lancet. 2003;361(9374):2005–2016
   PubMed Web of Science ®Google Scholar
• . Sacks FM, Pfeffer MA, Moye LA, ; Cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001–1009
   PubMed Web of Science ®Google Scholar
• . Downs JR, Clearfield M, Weis S, . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Ar Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–1622
   PubMed Web of Science ®Google Scholar
• . Ginsberg HN, Elam MB, Lovato LC; The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574
   PubMed Web of Science ®Google Scholar
• . Boden WE, Probstfield JL, Anderson T, ; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267
   PubMed Web of Science ®Google Scholar
• . Grundy SM, Cleeman JI, Merz NB, ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration; US Department of Health and Human Services. FDA expands advice on statins risk, http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm. Accessed June 20, 2012
   Google Scholar
• . Ridker PM, Danielson E, Fonseca FA, ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207
   PubMed Web of Science ®Google Scholar
• . Stratton IM, Adler AI, Neil HA, . Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
   PubMed Web of Science ®Google Scholar
• . Selvin E, Marinopoulos S, Berkenblit G, . Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431
   PubMed Web of Science ®Google Scholar
• . The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T, ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . Gerstein HC, Miller ME, Genuth S, ; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–828
   PubMed Web of Science ®Google Scholar
• . Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract. 2008;82(3):391–395
   PubMed Web of Science ®Google Scholar
• . Arruda—Olson AM, Patch RK 3rd, Leibson CL, . Effect on second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc. 2009;84(1):28–33
   PubMedGoogle Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA. 2003;290(4):486–494
   PubMed Web of Science ®Google Scholar
• . Dormandy JA, Charbonnel B, Eckland DJ, ; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macro Vascular Events): arandomised controlled trial. Lancet. 2005;366(9493):1279–1289
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Nicholls SJ, Wolski K, . PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471
   PubMed Web of Science ®Google Scholar
• . Wulffele MG, Kooy A, Lehert P, . Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care. 2002;25(12):2133–2140
   PubMed Web of Science ®Google Scholar
• . Kooy A, de Jager J, Lehert P, . Long-term effects on metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616–625
   PubMedGoogle Scholar
• . Gaziano JM, Cincotta AH, O'Connor CM, . Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33(7):1503–1508
   PubMed Web of Science ®Google Scholar
• . Lazar HL, Chipkin SR, Fitzgerald CA, . Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109(12):1497–1502
   PubMed Web of Science ®Google Scholar
• . Malmberg K, Norhammer A, Wedel H, Rydén L. Glycometabolic state at admission: important risk factor of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99(20):2626–2632
   PubMed Web of Science ®Google Scholar
• . Malmberg K, Rydén L, Efendic S, . Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26(1):57–65
   PubMed Web of Science ®Google Scholar